Rate or rhythm control in persistent atrial fibrillation?

QJM: An International Journal of Medicine

Volumn 96, Issue 12, 2003, Pages 881-892

  Boos, Christopher J ^a   Carlsson, J ^b   More, R S ^c  

^a PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^b KLINIKUM LIPPE DETMOLD   (Germany)

^c BLACKPOOL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; DIGOXIN; DILTIAZEM; DOFETILIDE; DRONEDARONE; PLACEBO; SOTALOL; VERAPAMIL; WARFARIN; XIMELAGATRAN;

AGING; ANTICOAGULANT THERAPY; CARDIOVERSION; CATHETER ABLATION; CLINICAL PRACTICE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; HEART ATRIOVENTRICULAR NODE; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART RATE; HEART RHYTHM; HEART SURGERY; HEART VENTRICLE FUNCTION; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SINUS RHYTHM; TACHYCARDIA; THROMBOEMBOLISM; TORSADE DES POINTES;

EID: 0346119926     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/hcg147     Document Type: Review

References (98)

1. Prystowsky EN, Benson DW Jr, Fuster V, Hart RG, Kay GN, Myerburg RJ, Naccarelli GV, Wyse DG. Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996; 6:1262-77.
2. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271:840-4.
3. Braunwald E. Shattuck lecture- Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997; 337:1360-9.
4. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155:469-3.
5. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82:2N.
6. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285:2370-5.
7. Carlsson J, Neuzner J, Rosenberg YD. Therapy of atrial fibrillation: Rhythm control versus rate control. Pacing Clin Electrophysiol 2000; 23:891-903.
8. Brodsky MA, Chun JG, Podrid PJ, Douban S, Allen BJ, Cygan R. Regional attitudes of generalists, specialists, and sub specialists about management of atrial fibrillation. Arch Intern Med 1996; 156:2553-62.
9. Donahue TP, Conti JB. Atrial fibrillation: rate control versus maintenance of sinus rhythm. Curr Opin Cardiol 2001; 16:46-53.
10. Redfield MM, Kay GN, Jenkins LS, Mianulli M, Jensen DN, Ellenbogen KA. Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo Clin Proc 2000; 75:790-5.
11. Petersen P, Kastrup J, Brinch K, Godtfredsen J, Boysen G. Relation between left atrial dimension and duration of atrial fibrillation. Am J Cardiol 1987; 60:382-4.
12. Aronow WS. Atrial fibrillation. Heart Dis 2002; 4:91-101.
13. Brodsky MA, Allen BJ, Walker CJ 3rd, Casey TP, Luckett CR, Henry WL. Amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 1987; 60:572-5.
14. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 2001; 22:1852-923.
15. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356:1789-94.
16. Van Gelder IC, Hagens VE, Bosker HA, et al. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) Study Group. N Engl J Med 2002; 347:1834-40.
17. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:825-33.
18. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, Tebbe U. STAF Investigators. Randomised trial of rate-control versus rhythm-control in persistent atrial fibrillations: STAF (Strategies of Treatment of Atrial Fibrillation) study. J Am Coll Cardiol 2003; 41:1690-6.
19. Opolski G, Torbicki A, Kosior D, Szulc M, Zawadzka M, Pierscinska M, Kolodziej P, Stopinski M, Achremczyk P, Wozakowska-Kaplon B, Rabczenko D. Rhythm control versus rate control in patients with persistent arial fibrillation. Results of the HOT CAFÉ Polish study. Kardiol Pol 2003; 59:1-16.
20. Gallagher MM, Camm AJ. Classification of atrial fibrillation. Pacing Clin Electrophysiol 1997; 20:1603-5.
21. Borgeat A, Goy JJ, Maendly R, Kaufmann U, Grbic M, Sigwart U. Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1986; 58:496-8.
22. Suttorp MJ, Kingma JH, Lie-A-Huen L, Mast EG. Intravenous flecainide versus verapamil for acute cardioversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol 1989; 63:93-6.
23. Suttorp MJ, Kingma JH, Jessurun ER, et al. The value of class IC antiarrhythmic drugs for acute cardioversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol 1990; 16:1722-7.
24. Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M, Billing CB Jr. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRED) study. Circulation 2000; 102:2385-90.
25. Greenbaum R, Campbell TJ, Channer KS. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetelide the EMERALD study. Circulation 1998; 989 (suppl.I):1-633.
26. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. AFFIRM First Antiarrhythmic Drug Substudy Investigators. J Am Coll Cardiol 2003; 42:20-9.
27. Letelier LM, Udol K, Ena J, Weaver B, Guyatt GH. Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm. Arch Intern Med 2003; 163:777-85.
28. Martin DO. Managing chronic atrial fibrillation: strategies to control symptoms and prevent embolism. Cleve Clin J Med 2003; 70 Suppl 3:S30-3.
29. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: A dose-ranging study. Eur Heart J 2003; 24:1481-7.
30. Dalzell GW, Anderson J, Adgey AA. Factors determining success and energy requirements for cardioversion of atrial fibrillation. Q J Med 1990; 76:903-13.
31. Boos C, Thomas M, Jones A, Clarke E, Wilbourne G, More R. Higher Energy Monophasic DC Cardioversion for Persistent Atrial Fibrillation: Is it Time to Start at 360 Joules? Ann Noninvasive Electrocardiol 2003; 8:121-126.
32. Lundstrom T, Ryden L. Chronic atrial fibrillation. Long-term results of direct current cardioversion. Acta Med Scand 1988; 223:53-9.
33. Bertaglia E, D'Este D, Zerbo F, Zoppo F, Delise P, Pascotto P. Success of serial external electrical cardioversion of persistent atrial fibrillation in maintaining sinus rhythm. A randomized study. Eur Heart J 2002; 23:1522-8.
34. Van Gelder IC, Crijns HJ, Tieleman RG, Brugemann J, De Kam PJ, Gosselink AT, Verheugt FW, Lie KI. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 1996; 156:2585-92.
35. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, Kus T, Lambert J, Dubuc M, Gagne P, Nattel S, Thibault B. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of atrial Fibrillation Investigators. N Engl J Med 2000; 342:913-20.
36. Van Gelder IC, Crijns HJ, Van Gilst WH, Verwer R, Lie KI. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardol 1991; 68:41-6.
37. Tieleman RG, Van Gelder IC, Crijns HJ, De Kam PJ, Van Den Berg MP, Haaksma J, Van Der Woude HJ, Allessie MA. Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria. J Am Coll Cardiol 1998; 31:167-73.
38. Frick M, Frykman V, Jensen-Urstad M, Ostergren J, Rosenqvist M. Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation. Clin Cardiol 2001; 24:238-44.
39. Dittrich HC, Erickson JS, Schneiderman T, Blacky AR, Savides T, Nicod PH. Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. Am J Cardiol 1989; 63:193-7.
40. Coro L, Delise P, Bertaglia E, Mozzato MG, Fantinel M, Bilardo G, D'Este D, Pascotto P. The duration of atrial fibrillation influences the long-term efficacy of low-energy internal cardioversion. Ital Heart J 2001; 2:388-93.
41. Duytschaever M, Haerynck F, Tavernier R, et al. Factors influencing long term persistence of sinus rhythm after a first electrical cardioversion for atrial fibrillation. Pacing Clin Electrophysiol 1998; 21 (1 Pt 2):284-7.
42. Di Pasquale G, Biancoli S, Sassone B, et al. Atrial Fibrillation. Always Cardioversion? No. Ital Heart J 2002; 3(1 suppl): 81-90.
43. Houghton AR, Sharman A, Pohl JE. Determinants of successful direct current cardioversion for atrial fibrillation and flutter: the importance of rapid referral. Br J Gen Pract 2000; 50:710-11.
44. Okcun B, Yigit Z, Kucukoglu MS, Mutlu H, Sansoy V, Guzelsoy D, Uner S. Predictors for maintenance of sinus rhythm after cardioversion in patients with nonvalvular atrial fibrillation. Echocardiography 2002; 19:351-7.
45. Hylek EM, Skates SJ, Sheehan MA and Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation in for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335:540-6.
46. Asher CR, Klein AL. The ACUTE trial. Transesophageal echocardiography to guide electrical cardioversion in atrial fibrillation. Assessment of Cardioversion Using Transesophageal Echocardiography. Cleve Clin J Med 2002; 69:713-18.
47. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Metayer P, Clementy J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339:659-66.
48. Chen SA, Tai CT, Tsai CF, Hsieh MH, Ding YA, Chang MS. Radiofrequency catheter ablation of atrial fibrillation initiated by pulmonary vein ectopic beats. Cardiovasc Electrophysiol 2000; 11:218-27.
49. Lau CP, Tse HF, Ayers GM. Defibrillation-guided radio-frequency ablation of atrial fibrillation secondary to an atrial focus. J Am Coll Cardiol 1999; 33:1217-26.
50. Haissaguerre M, Jais P, Shah DC, Garrigue S, Takahashi A, Lavergne T, Hocini M, Peng JT, Roudaut R, Clementy J. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation 2000; 101:1409-17.
51. Haissaguerre M, Shah DC, Jais P, Hocini M, Yamane T, Deisenhofer I, Chauvin M, Garrigue S, Clementy J. Electrophysiological breakthroughs from the left atrium to the pulmonary veins. Circulation 2000; 102:2463-5.
52. Macle L, Jais P, Weerasooriya R, Hocini M, Shah DC, Choi KJ, Scavee C, Raybaud F, Clementy J, Haissaguerre M. Irrigated-Tip Catheter Ablation of Pulmonary Veins for Treatment of Atrial Fibrillation. J Cardiovasc Electrophysiol 2002; 13:1067-73.
53. Martin DO, Saliba W, McCarthy PM, Gillinov AM, Belden W, Marrouche NF, Natale A. Approaches to restoring and maintaining normal sinus. Cleve Clin J Med 2003I; 70 Suppl 3:S12-29.
54. Marrouche NF, Dresing T, Cole C, Bash D, Saad E, Balaban K, Pavia SV, Schweikert R, Saliba W, Abdul-Karim A, Pisano E, Fanelli R, Tchou P, Natale A. Circular mapping and ablation of the pulmonary vein for treatment of atrial fibrillation: impact of different catheter technologies. Am Coll Cardiol 2002; 40:464-74.
55. Ng FS, Camm AJ. Catheter ablation of atrial fibrillation. Clin Cardiol 2002; 25:384-94.
56. Marrouche NF, Martin DO, Wazni O, Gillinov AM, Klein A, Bhargava M, Saad E, Bash D, Yamada H, Jaber W, Schweikert R, Tchou P, Abdul-Karim A, Saliba W, Natale A. Phased-array intracardiac echocardiography monitoring during pulmonary vein isolation in patients with atrial fibrillation: impact on outcome and complications. Circulation 2003; 107:2710-16.
57. Pappone C, Rosanio S, Augello G, Gallus G, Vicedomini G, Mazzone P, Gulletta S, Gugliotta F, Pappone A, Santinelli V, Tortoriello V, Sala S, Zangrillo A, Crescenzi G, Benussi S, Alfieri O. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 2003; 42:185-97.
58. Arentz T, Jander N, von Rosenthal J, Blum T, Furmaier R, Gornandt L, Josef Neumann F, Kalusche D. Incidence of pulmonary vein stenosis 2 years after radiofrequency catheter ablation of refractory atrial fibrillation. Eur Heart J 2003; 24:963-9.
59. Pappone C. Pulmonary vein stenosis after catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol 2003; 14:165-7.
60. Saad EB, Marrouche NF, Saad CP, Ha E, Bash D, White RD, Rhodes J, Prieto L, Martin DO, Saliba WI, Schweikert RA, Natale A. Pulmonary vein stenosis after catheter ablation of atrial fibrillation: emergence of a new clinical syndrome. Ann Intern Med 2003; 138:634-8.
61. Moe GK. On the multiple wavelet hypothesis of atrial fibrillation. Arch Int Pharmacodyn Ther 1962; 140:183-8.
62. Cox JL, Schuessler RB, Cain ME, Corr PB, Stone CM, D'Agostino HJ Jr, Harada A, Chang BC, Smith PK, Boineau JP. Surgery for atrial fibrillation. Semin Thorac Cardiovasc Surg 1989; 1:67-73.
63. Cox JL, Ad N, Palazzo T, Fitzpatrick S, Suyderhoud JP, DeGroot KW, Pirovic EA, Lou HC, Duvall WZ, Kim YD. Current status of the Maze procedure for the treatment of atrial fibrillation. Semin Thorac Cardiovasc Surg 2000; 12:15-9.
64. Cox JL, Ad N, Palazzo T. Impact of the maze procedure on the stroke rate in patients with atrial fibrillation. J Thorac Cardiovasc Surg 1999; 118:833-40.
65. McCarthy PM, Gillinov AM, Castle L, Chung M, Cosgrove D 3rd. The Cox-Maze procedure: the Cleveland Clinic experience. Semin Thorac Cardiovasc Surg 2000; 12:25-9.
66. Lonnerholm S, Blomstrom P, Nilsson L, Oxelbark S, Jideus L, Blomstrom-Lundqvist C. Effects of the maze operation on health-related quality of life in patients with atrial fibrillation. Circulation. 2000; 101:2607-11.
67. Rawles JM. What is meant by a 'controlled' ventricular rate in atrial fibrillation? Br Heart J 1990; 63:157-61.
68. Resnekov L, Mc Donald L. Electroversion of lone atrial fibrillation and flutter including haemodynamic studies at rest and exercise. Br Heart J 1971; 33:339-50.
69. Rodney H, Falk MD. Atrial Fibrillation. N Engl J Med 2001; 344:1067-78.
70. Schreck DM, Rivera AR, Tricarico VJ. Emergency management of atrial fibrillation: intravenous diltiazem versus intravenous digoxin. Ann Emerg Med 1997; 29:135-40.
71. Botker HE, Toft P, Klitgaard NA, Simonsen EE. Influence of physical exercise on serum digoxin concentration and heart rate in patients with atrial fibrillation. Br Heart J 1991; 65:337-41.
72. Goldman S, Probst P, Selzer A, Cohn K. Inefficiency of 'therapeutic' serum levels of digoxin in controlling the ventricular rate in atrial fibrillation. Am J Cardiol 1975; 35:651-55.
73. Farshi R, Kistner D, Sarma JSM, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol 1999; 33:304-10.
74. Roth A, Harrison E, Mitani G, et al. Efficacy and safety of medium and high-dose diltiazem alone or in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation 1986; 73:316-24.
75. Pnadis IP, Morganroth J, Baessler C. Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis. Am J Cardiol 1983; 52:1197-201.
76. Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmia. Am J Cardiol 1998; 81:594-8.
77. Daoud EG, Weiss R, Bahu M, Knight BP, Bogun F, Goyal R, Harvey M, Strickberger SA, Man KC, Morady F. Effect of irregular ventricular rhythm on cardiac output. Am J Cardiol 1996; 78:1433-36.
78. Brignole M, Menozzi C, Gianfranchi L, Musso G, Mureddu R, Bottoni N, Lolli G. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized controlled study. Circulation 1998; 98:953-60.
79. Weerasooriya R, Davis M, Powell A, Szili-Torok T, Shah C, Whalley D, Kanagaratnam L, Heddle W, Leitch J, Perks A, Ferguson L, Bulsara M. The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). J Am Coll Cardiol 2003; 41:1697-702.
80. Ozcan C, Jahangir A, Friedman PA, Patel PJ, Munger TM, Rea RF, Lloyd MA, Packer DL, Hodge DO, Gersh BJ, Hammill SC, Shen WK. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med 2001; 3441:1043-51.
81. The AF-CHF-Investigators. Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: The atrial fibrillation and congestive heart failure (AF-CHF) trial. Am Heart J 2002; 144:597-607.
82. McHorney CA, Ware JE, Raczek AE. The MOS 36-item short-form health survey (SF-36), II: psychometric and clinical tests validity in measuring physical and mental health constructs. Med Care 1993; 31:247-63.
83. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. I Clinical features of patients at risk. Ann Intern Med 1992; 116:1-5.
84. Predictors of thromboembolism in atrial fibrillation. II. Echocardiographic features of patients at risk. Ann Intern Med 1992; 116:6-12.
85. Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 1999; 131:688-95.
86. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991; 84:527-39.
87. The National Heart, Lung and Blood Institute Working Group on Atrial Fibrillation: current understandings and research perspectives. J Am Coll Cardiol 1993; 22:1830-4.
88. Waldo AL. Management of atrial fibrillation and the need for AFFIRMative action. Am J Cardiol 1999; 84:698-700.
89. Crijns HJ, Van Gelder IC, Van Gilst WH, Hillege H, Gosselink AM, Lie KI. Serial antiarrhythmic drug treatments to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol 1991; 68:335-41.
90. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE. Antithrombotic treatment in atrial fibrillation. Chest 1998; 114:579-89S.
91. Boos CJ, More RS, Carlsson J. Persistent atrial fibrillation: rate control or rhythm control. Rate control is not inferior to rhythm control. Br Med J 2003; 326:1411-12.
92. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic treatment to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131:492-501.
93. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348:633-8.
94. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335:540-6
95. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischaemia. N Engl J Med 1995; 333:5-10.
96. Petersen P, Grind M, Adler J; SPORTIF II Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol 2003; 41:1445-51.
97. Halperin JL; Executive Steering Committee, SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with non-valvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003; 146:431-8.
98. Pietrsik A, Kosior D, Niewada M, Rabczenko D, Opolski G. One-year cost-effectiveness of rhythm and rate-control strategy in persistent atrial fibrillation. Eur Heart J 2003; 368:1999 (abstract Suppl).